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Skin and soft tissue infections (SSTI) are among the most commonly occurring infections and 24 
evidence suggests that these are increasing world-wide. The aetiology is diverse, but 25 
Staphylococcus aureus predominate and these are often resistant to antimicrobials that 26 
were previously effective. Tedizolid is a new oxazolidinone-class antibacterial indicated for 27 
the treatment of adults with SSTI caused by Gram-positive pathogens, including S. aureus.  28 
 29 
The aim of this study was to evaluate the in vitro efficacy of tedizolid in comparison to other 30 
clinically used antibacterials against antibiotic sensitive- and resistant-staphylococci, grown 31 
in planktonic cultures and as biofilms reflecting the growth of the microorganism during 32 
episodes of SSTI.  33 
 34 
Against a panel of 66 clinical staphylococci, sensitivity testing revealed that a lower 35 
concentration of tedizolid was required to inhibit the growth of staphylococci compared to 36 
linezolid, vancomycin and daptomycin; with the tedizolid MIC50 being 8-fold (S. aureus) or 4-37 
fold (S. epidermidis) below that obtained for linezolid. In addition, cfr+ linezolid-resistant 38 
strains remained fully susceptible to tedizolid. Against S. aureus biofilms, 10×MIC tedizolid 39 
was superior or comparable with 10×MIC comparator agents in activity, and superior to 40 
10×MIC linezolid against those formed by S. epidermidis (65 vs. 33% reduction, respectively). 41 
Under flow-conditions both oxazolidinones at 10×MIC statistically out-performed 42 
vancomycin in their ability to reduce the viable cell count within a S. aureus biofilm with 43 




In conclusion, tedizolid offers a realistic lower-dose alternative agent to treat staphylococcal 46 
SSTI, including infections caused by multi-drug resistant strains. 47 
 48 
Keywords: skin and soft tissue infections, tedizolid, linezolid, staphylococcus, biofilm, 49 
minimum inhibitory concentration 50 
 51 
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EUCAST, European Committee on Antimicrobial Susceptibility Testing 56 
GMO, genetically modified organism 57 
LZD, linezolid 58 
MRSA, methicillin resistant Staphylococcus aureus 59 
MSSA, methicillin sensitive Staphylococcus aureus 60 
MIC, minimum inhibitory concentration 61 
MHB, Mueller-Hinton broth 62 
PBS, phosphate buffered saline 63 
SSTI, skin and soft tissue infection 64 
TZD, tedizolid 65 
VAN, vancomycin 66 
VISA, vancomycin intermediate susceptibility S. aureus  67 
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1. Introduction 68 
Skin and soft tissue infections (SSTIs) are common within both hospitalised patients and 69 
individuals within the community, yet providing a suitable treatment remains a clinical 70 
challenge. Published national and international guidelines for the treatment of SSTIs broadly 71 
agree [1]. The United Kingdom’s National Institute for Clinical Excellence (NICE) guidelines, 72 
for example, emphasise the importance of using empirical treatment effective against 73 
methicillin resistant Staphylococcus aureus (MRSA) [1]. With the subsequent knowledge of 74 
bacterial cultures, treatment can be de-escalated to a narrow spectrum agent, preferably 75 
with oral administration allowing treatment to continue in the community. In reality, a 76 
microbiological diagnosis may not be available and initial therapy inadequate leading to 77 
clinical failure, recurrence of infection and readmission to hospital increasing the overall 78 
length of patient stay. Complicating therapy further, resistant Staphylococcus aureus can be 79 
responsible for in the region of half of complicated SSTIs, yet empirical therapy is often not 80 
appropriate for these microorganisms [2]. 81 
 82 
Currently vancomycin, linezolid, daptomycin, ceftaroline and telavancin are among those 83 
antibacterials recommended for the treatment of severe SSTIs with other agents in reserve 84 
for milder infections [3]. Newer agents are becoming available, including tedizolid, 85 
dalbavancin and oritavancin, but clinical evidence for the role of these agents is limited and 86 
needs to be provided if future guidelines are to be established [4].  87 
 88 
Tedizolid phosphate (Sivextro®) is a next-generation oxazolidinone antibacterial approved 89 
for the treatment of adults with acute SSTIs caused by susceptible Gram–positive 90 
microorganisms, including staphylococci  [5]. The spectrum of activity is similar to linezolid, 91 
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though activity is retained against some strains that are resistant to linezolid [6]. Similar in 92 
mode of action to other oxazolidinones, antibacterial activity is mediated by inhibiting 93 
protein synthesis [7]. 94 
Tedizolid is a new drug approved for the treatment of SSTIs in a number of countries, 95 
including the United States, Cananda and the European Union [4]. The aim of this study was 96 
to evaluate the in vitro efficacy of tedizolid in comparison to other clinically used 97 
antibacterials against antibiotic sensitive and resistant staphylococci, grown in planktonic 98 
cultures and as biofilms reflecting the growth of the microorganism during episodes of SSTI. 99 
  100 
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2. Material and Methods 101 
2.1. Strains, culture conditions and preparation of antibiotics 102 
The study included 66 clinical staphylococcal isolates: 27 methicillin sensitive S. aureus 103 
(MSSA) (including two linezolid-resistant), 27 MRSA (including two linezolid-resistant) and 104 
12 Staphylococcus epidermidis (including two linezolid-resistant). Except the six linezolid-105 
resistant strains (provided by J. Mingorance, Madrid), all strains were supplied by the 106 
Scottish MRSA Reference Laboratory, Glasgow (Supplementary Table 1). 107 
 108 
All experiments were performed in Mueller-Hinton broth (MHB, Oxoid); for testing with 109 
daptomycin the medium was supplemented with 50 mg/L Ca2+ [8].  110 
 111 
Tedizolid and linezolid were gifted by MSD and Pfizer, respectively (MSD, Hertfordshire, UK; 112 
Pfizer Ltd, Surrey, UK). Vancomycin and daptomycin were purchased from Sigma-Aldrich 113 
(Dorset, UK). Stock solutions of tedizolid were prepared in dimethyl sulfoxide (DMSO, 1,600 114 
mg/L) prior to 2-fold dilutions in DMSO as per the supplier’s guidelines. Other antibiotic 115 
stocks of 10,000 mg/L (except linezolid 1,000 mg/L) were prepared using distilled water and 116 
used or stored at -20°C for a maximum of two weeks.  117 
 118 
2.2. Antibiotic susceptibility of staphylococcal planktonic cultures 119 
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration 120 
(MBC) were evaluated for vancomycin, daptomycin and linezolid according to EUCAST 121 
guidelines [8]. For tedizolid, using 96-well plates, 2 µL of the relevant 50× tedizolid was 122 
combined with 98 µL of an overnight culture adjusted to 5×105 cfu/mL. S. aureus ATCC 123 
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29213 was included as a control strain; all results were within guideline limits. MIC/MBCs 124 
were repeated independently at least three times. 125 
 126 
2.3 Time-kill assays 127 
The time-kill kinetics were determined for two MRSA isolates; one linezolid-sensitive and 128 
one linezolid-resistant. Overnight cultures were diluted to a final concentration of 1×106 129 
cfu/mL in 50 mL fresh MHB (antibiotic-free control) and MHB supplemented with each 130 
antibiotic (tedizolid, linezolid and vancomycin) at a concentration of 0.25×, 1× and 10×MIC 131 
and then incubated at 37°C with aeration at 200rpm for 24 h. Aliquots of 1 mL were 132 
removed at time zero and then every 30 minutes for the first 6 h and finally 24 h post-133 
inoculation and viable counts obtained. Experiments were performed in triplicate. 134 
 135 
2.4. Antibiotic susceptibility of biofilms 136 
Twenty robust biofilm forming strains, selected using the crystal violet staining technique 137 
(data not shown),  were evaluated for antibacterial susceptibility whilst in a biofilm mode of 138 
growth; 5 each MRSA, MSSA, S. epidermidis and linezolid-resistant Staphylococcus strains. 139 
Overnight cultures adjusted to 1×106 cfu/mL were inoculated into 96-well plates and 140 
incubated for 24 h at 37°C on a rocking platform (60 oscillations/min). Then, supernatants 141 
were removed, biofilms washed three times with phosphate buffered saline (PBS, Oxoid) 142 
and 150 µL of antibiotic supplemented MHB added at concentrations of 0.25×, 1×, 10× or 143 
100×MIC (except where 100×MIC exceeded Cmax). Antibiotic-free controls were included. 144 
After 24 h antibiotic exposure at 37°C, 0.001% (v/v) resazurin (Sigma) in PBS was added to 145 
each washed biofilm and incubated at 37°C in the dark for 2 h, then fluorescence measured 146 
(EM590nm/EX540nm) using a plate reader (FLUOstar Optima, BMG Labtech, Germany), 147 
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providing an indirect measure of the viable cells. The experiment was repeated on two 148 
further occasions. Any significant outliers among technical replicates were determined using 149 
Grubbs’ test (p-value <0.05) and excluded from further analysis. Using the fluorescence 150 
readings, the percentage of cells surviving within an antibiotic-treated biofilm was 151 
determined by comparison with the untreated control. Statistical difference between 152 
treated and untreated biofilms was determined using Student’s t-test and GraphPad Prism 7 153 
Software. 154 
 155 
2.5. Tedizolid susceptibility of biofilms under flow-conditions 156 
A flow-cell system was used to evaluate susceptibility under conditions replicating the in 157 
vivo environment. Three silicone coupons were place in each of two chambers of a FC 275 158 
flow-cell (BioSurface Technologies Corporation, Montana, USA) and MHB introduced into 159 
the system via two reservoirs. Using overnight cultures of MSSA31, the coupons were 160 
inoculated with 1×106 cfu/mL and maintained under static conditions for 1 h at 37°C to aid 161 
attachment, and then media flow (1 mL/minute) continued for 3 days during biofilm 162 
formation. Subsequently, one reservoir was replaced with fresh MHB (antibiotic-free 163 
control) and the second with MHB supplemented with 10×MIC tedizolid, linezolid or 164 
vancomycin and flow resumed for a further 24 h at 37°C. Finally, the coupons were 165 
removed, rinsed and individually sonicated 3×5 minutes in PBS using a sonicating waterbath 166 
and viable counts determined. Each experiment was performed either in duplicate or 167 
triplicate. Percentage cell survival was calculated (section 2.4) and statistical difference 168 
between treated and untreated biofilms determined using Student’s t-test. 169 
  170 
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3. Results  171 
3.1. Antibiotic susceptibility of planktonic cultures 172 
The MICs and MBCs were determined against the 66 staphylococci (Supplemental Data 173 
Table 1). There was no evidence of resistance to any of the antibiotics tested, except for the 174 
Spanish strains that were resistant to linezolid, and all the MIC ranges and MIC50 values for 175 
linezolid, vancomycin and daptomycin were as expected being within one-dilution of the 176 
EUCAST published data [8] (Supplemental Data Table 1). All the linezolid-sensitive strains 177 
were highly susceptible to tedizolid with MICs within the narrow range of 0.125-0.5 mg/L; a 178 
median MIC value 8-fold below that of linezolid. The tedizolid sensitivity of linezolid-179 
resistant strains varied with the resistance mechanism; those cfr+ had a tedizolid MIC of 180 
0.25-0.5 mg/L (versus 8 mg/L linezolid), those that possessed the G2576T mutation had 181 
tedizolid MIC values of 2-4 mg/L (versus 16-64 mg/L linezolid), whilst the strain exhibiting 182 
both linezolid-resistance mechanisms had MIC values of 4 mg/L tedizolid and 512 mg/L 183 
linezolid.   184 
 185 
Vancomycin and daptomycin were shown to be bactericidal, with only 16% and <1% of 186 
isolates presenting with a MBC:MIC ratio >8. By contrast linezolid and tedizolid were 187 
bacteriostatic (Supplemental Data Table 1).  188 
 189 
3.2 Time-kill kinetics 190 
Time-kill kinetics were determined for tedizolid, linezolid and vancomycin for two MRSA 191 
strains; one sensitive (MRSA23) and one resistant (cfr+ JM02) to linezolid (Fig.1). Sub-MIC 192 
antibiotic exerted minimal effect on the growth of the organisms with viable bacterial cell 193 
concentrations remaining similar to the untreated control. At 1× and 10×MIC tedizolid was 194 
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bacteriostatic against both isolates with activity against the linezolid-resistant strain 195 
comparable to that exerted against the sensitive strain (Fig.1). Despite initially impeding 196 
growth, 1×MIC linezolid failed to inhibit growth of cfr+ JM02 with a 2-log increase in 197 
bacterial cell number compared to the initial inoculum after 24 h exposure to the agent 198 
(10×MIC exceeded the therapeutically achievable concentration and was not tested). 199 
Conversely, a >3-log reduction in viable cell number in comparison to the initial inoculum 200 
was attained after 24 h exposure to 1× and 10×MIC vancomycin confirming the bactericidal 201 
nature of the agent. 202 
 203 
3.3. Antibiotic susceptibility of biofilms 204 
A dose-dependent response was noted for biofilms challenged with each antibacterial. At a 205 
concentration of 1×MIC, no agent was able to reduce the proportion of viable cells within 206 
the biofilm to 60% or fewer of untreated control biofilm; vancomycin in particular had little 207 
if any impact (Fig.2a). The mean level of activity exerted against S. epidermidis isolates (77-208 
107% mean survival) by each antibacterial was inferior to that exhibited against the S. 209 
aureus isolates (64-103% mean survival), an effect that was of particular note with linezolid 210 
(103% vs 64% mean survival, S. epidermidis and S. aureus respectively).  211 
 212 
When challenged with 10×MIC antibacterial there was a marked reduction in the proportion 213 
of cells within the biofilm remaining viable (28-77% mean cells remaining viable) (Fig.2b). 214 
Against S. aureus all of the agents tested reduced the biofilm to below a 50% mean of the 215 
untreated control (28-45% mean cell survival) compared to S. epidermidis where only 216 
vancomycin and tedizolid attained a comparable reduction (29 and 35% mean cell survival, 217 
respectively); linezolid and daptomycin achieved only a 33% and 47% mean decrease in 218 
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viable cells, respectively, with the majority of cells remaining viable after treatment. In 219 
addition to the greater level of tolerance exhibited by S. epidermidis isolates, there was also 220 
greater variation in susceptibility between the strains.  At least one S. epidermidis isolate 221 
was unaffected by 10×MIC of any agent tested (97-103% cell viability), the exception being 222 
tedizolid which retained a good level of activity against all the S. epidermidis strains tested, 223 
including the linezolid-resistant strains. 224 
 225 
Under flow-conditions tedizolid was superior to vancomycin and comparable to linezolid in 226 
the ability to reduce the proportion of viable biofilm-associated cells remaining on the 227 
silicone coupons (Fig.3). Exposure to 10xMIC tedizolid or linezolid led to a statistically 228 
significant reduction in the proportion of viable cells remaining within the biofilm (8%, p 229 
<0.05 or 12%, p <0.005 cell survival compared to the untreated control, respectively) while 230 
vancomycin did not achieve a statistically significant reduction in viable cells (63%, p=0.08).  231 
  232 
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4. Discussion and Conclusion 233 
Ranging from mild to life-threatening, SSTI are among the most commonly occurring 234 
infections and evidence suggests that these are increasing. From 1993-2005, the number of 235 
emergency department visits in the USA by patients with these presentations increased 236 
from 1.2 million visits to 3.4 million [9].  Whilst SSTIs are diverse in aetiology, S. aureus are 237 
consistently predominating world-wide with multi-drug resistant strains increasingly being 238 
reported [10]. In the USA, one study reported that 81% of culture-positive SSTIs were 239 
caused by S. aureus, with almost half (46%) of those strains recovered being resistant to 240 
methicillin [11]. The high prevalence of the USA300 MRSA strain may account in part for 241 
these figures. In Europe however, where USA300 remains typically rare, a similar profile is 242 
seen. Morrissey et al. (2012) reported that approximately one half of SSTIs caused by S. 243 
aureus were MRSA [12]. As such, SSTIs pose an immense, and increasing, physical and 244 
economic burden to healthcare providers. 245 
 246 
Achieving an effective treatment combining surgical debridement or drainage with empirical 247 
antibiotic therapy is not without its challenges. From the microbiological prospective, the 248 
agent is often unknown, multidrug-resistance is prevalent and a biofilm mode of growth 249 
complicates therapy. Though more prevalent in chronic wounds with 60% of samples being 250 
positive, biofilms have also been detected in 6% of acute wounds [13]. In this study, the 251 
increased activity of tedizolid compared to linezolid and other anti-staphylococcal agents 252 
was achieved typically using lower concentrations against both planktonic and biofilm-253 
associated cells, including cfr+ multidrug-resistant strains. Against S. aureus biofilms, 254 
tedizolid was superior or comparable with comparator agents in activity, and typically 255 
superior against those formed by S. epidermidis strains. Under flow-conditions mimicking 256 
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the in vivo environment of a SSTI, for example infection related to an indwelling-device, the 257 
bacteriostatic oxazolidinones both out-performed vancomycin.  258 
 259 
Vancomycin has been a mainstay of treatment for staphylococcal SSTI. However, the 260 
decreased susceptibility observed in vancomycin intermediate susceptibility S. aureus (VISA) 261 
and strains displaying heteroresistance, the need for intravenous slow-infusion and to 262 
monitor serum levels, and the potential for toxicity have led to moves towards other 263 
antibacterial agents. The alternatives currently available include linezolid, telavancin and 264 
daptomycin. Linezolid has been shown to be more effective at treating SSTIs than 265 
vancomycin with fewer complications being reported and patient discharge occurring 266 
sooner [14]. Whilst linezolid retains a good level of activity against staphylococci [15], the 267 
emergence of linezolid resistance in staphylococci is a concern [16]. Tedizolid has however, 268 
been demonstrated by this study to retain activity against cfr+ staphylococci. It has 269 
previously been reported that the sterically compact nature of the hydroxymethyl group of 270 
tedizolid greatly improves activity against strains possessing the cfr gene [6]. In addition, 271 
tedizolid was reported by Russo et al. (2016) to be statistically non-inferior to linezolid in 272 
patients with SSTI for an early clinical response evaluated 48–72 h after beginning therapy 273 
[17]. Other factors favouring the use of tedizolid over contemporary agents in the treatment 274 
of SSTI include the long half-life (double linezolid) allowing once a day dosing, short course 275 
duration and an easy switch from intravenous to oral administration. It is recognised that 276 
these studies are undertaken in vitro and as such cannot infer in vivo activity, however, the 277 





In conclusion, in this in vitro study the anti-staphylococcal activity of tedizolid has been 281 
shown to be at least comparable and often superior to comparator agents that are routinely 282 
prescribed in the treatment of SSTIs. Taken with the drive to de-escalate SSTI treatment 283 
sooner, switching early to a short-course oral agent allowing early discharge, tedizolid offers 284 
a realistic lower dose alternative agent in the treatment of staphylococcal SSTI, including 285 
those where biofilms are present. 286 
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Figure Legends  362 
Figure 1. Time-kill kinetics of linezolid sensitive MRSA23 (a,c,e) and linezolid resistant MRSA 363 
(cfr+) JM02 (b,d,f) challenged with (a,b) tedizolid, (c,d) linezolid and (e,f) vancomycin at 364 
concentrations of 0.25xMIC (♦), 1xMIC (), 10xMIC (), compared to untreated control 365 
cultures (•). Error bars represent SEM between replicate samples (n = 3). Broken line (….) 366 
indicates a 3-log reduction in viable cell number in comparison to the initial inoculum. cfu, 367 
colony forming units. 368 
 369 
Figure 2. Susceptibility of biofilm-associated staphylococcal cells exposed to (a) 1×MIC or (b) 370 
10×MIC antibiotic compared to untreated control cultures. Antibiotics included VAN, 371 
vancomycin; DAP, daptomycin; LZD, linezolid; TZD, tedizolid. Cell survival was assessed using 372 
the metabolic dye resazurin. Each experiment consisted of four replicate biofilms and was 373 
repeated a further two times. Error bars represent SEM. 374 
 375 
Figure 3. Susceptibility of MSSA31 biofilm-associated cells cultivated on silicone rubber 376 
coupons and exposed to 10xMIC antibiotic under flow conditions within a BST flow-cell 377 
system. Antibiotics included VAN, vancomycin; LZD, linezolid; and TZD, tedizolid. Paired t-378 
test; ** p-value < 0.05; **** p-value < 0.005; no asterisk p > 0.05. Each experiment 379 
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 Supplementary Table 1. Origin of the strains used in this study. 
Staphylococcus 
species Strain Sample type  Origin
a Isolated Comments 
Methicillin resistant 
S. aureus  
(MRSA) 
n = 27 
MRSA1 - 25 Blood Scottish hospitals 2014-2015 spa typedb 
JM01 nk Madrid, Spain nk Linezolid resistant (cfr+) 
JM02 nk Madrid, Spain nk Linezolid resistant (cfr+) 
Methicillin sensitive 
S. aureus  
(MSSA) 
n = 27 
MSSA25 - 50 Blood Scottish hospitals 2014-2015 spa typedb 
JM03 nk Madrid, Spain nk Linezolid resistant (G2576T mutation)  
JM04 nk Madrid, Spain - Linezolid resistant GMO; cfr
+ transconjugant of 
strain ATCC 29213 
ATCC 29213 - Reference strain - Antibiotic sensitivity control strain 
S. epidermidis 
n = 12  
JM05 nk Madrid, Spain nk Linezolid resistant (G2576T mutation)  
JM06 nk Madrid, Spain nk Linezolid resistant (cfr+  and G2576T mutation) 
10, 70, 93, 96, 103, 105, 




Scottish hospitals 2011-13 - 
a; Hospital Universitario La Paz, Madrid or Scottish MRSA Reference Laboratory (SMRSARL), Glasgow Royal Infirmary, Glasgow. 
b;Isolates represented 32 different spa types (1-9 representatives per spa type with t032 being predominant) and 12 clonal complexes (with CC22, n = 20; 
CC5, n = 6; and CC30, n = 5 being the principal types).  
nk; not known. 
 
Supplemental Table 2. Antibiotic susceptibility of staphylococci grown in planktonic culture.  
 
Antibacterial Organism Antibiotic susceptibility (mg/l) 
  MIC range MIC50 MIC90 MBC50 MBC90 MBC50 / MIC50 
Tedizolid MSSA 0.125 - 2 0.25 0.5 4 4 16 
 MRSA 0.125 - 0.5 0.25 0.5 2 4 8 
 S. epidermidis 0.25 - 4 0.25 4 4 > 4 16 
Linezolid MSSA 2 - 16 2 4 16 > 16 8 
 MRSA 2 - 8 2 4 16 > 16 8 
 S. epidermidis 1 - 512 1 64 32 64 32 
Vancomycin MSSA 0.25 - 1 0.5 1 2 4 2 
 MRSA 0.25 - 1 0.5 1 2 > 8 2 
 S. epidermidis 1 - 2 1 2 2 4 2 
Daptomycin MSSA 0.25 - 1 0.5 1 1 2 2 
 MRSA 0.5 - 1 0.5 1 1 2 2 
 S. epidermidis 0.5 - 2 0.5 1 0.5 2 1 
MSSA, n = 27 including 2 linezolid resistant strains; MRSA, n = 27 including 2 linezolid resistant strains; S. epidermidis, n = 12 including 2 linezolid resistant 
strains. 
